Hadeel Hassan, Yujie Chen, Amy Duoli Lu, Santiago Eduardo Arciniegas, Adam Paul Yan, Lin Lawrence Guo, Lillian Sung
{"title":"Systematic Review of Studies Investigating Hospital Readmissions in Pediatric Oncology.","authors":"Hadeel Hassan, Yujie Chen, Amy Duoli Lu, Santiago Eduardo Arciniegas, Adam Paul Yan, Lin Lawrence Guo, Lillian Sung","doi":"10.1002/pbc.31459","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This systematic review aimed to identify and synthesize evidence on hospital readmissions among pediatric oncology patients, focusing on the indications, risk factors, and proposed strategies to prevent readmissions.</p><p><strong>Method: </strong>The review followed PRISMA 2020 guidelines. Databases including Embase, Medline, Scopus, Mendeley, and Google Scholar were searched. Studies examining hospital readmission as a main outcome in pediatric cancer patients, including those undergoing surgical oncology procedures or receiving hematopoietic cell transplantation, were included. Quality assessment was undertaken using the Newcastle-Ottawa Scale and PROBAST tool.</p><p><strong>Results: </strong>A total of 18 studies met the inclusion criteria. The studies spanned from 2008 to 2023, with an increase in publications from 2020 onward (61%). Fever and infection were the most common readmission indications. Statistically significant risk factors reported included younger age, specific cancer types (e.g., acute lymphoblastic leukemia), and socioeconomic factors. Prevention strategies proposed included early follow-up, tailored anticipatory guidance, discharge education, and specialized care at pediatric oncology centers.</p><p><strong>Conclusions: </strong>This systematic review highlights the multifaceted nature of hospital readmissions in pediatric oncology patients and the need for standardized definitions, additional studies, and comprehensive interventions. Future research should focus on high-quality prospective studies, integration of predictive analytics, and addressing socioeconomic disparities to improve patient outcomes.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31459"},"PeriodicalIF":2.4000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pbc.31459","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: This systematic review aimed to identify and synthesize evidence on hospital readmissions among pediatric oncology patients, focusing on the indications, risk factors, and proposed strategies to prevent readmissions.
Method: The review followed PRISMA 2020 guidelines. Databases including Embase, Medline, Scopus, Mendeley, and Google Scholar were searched. Studies examining hospital readmission as a main outcome in pediatric cancer patients, including those undergoing surgical oncology procedures or receiving hematopoietic cell transplantation, were included. Quality assessment was undertaken using the Newcastle-Ottawa Scale and PROBAST tool.
Results: A total of 18 studies met the inclusion criteria. The studies spanned from 2008 to 2023, with an increase in publications from 2020 onward (61%). Fever and infection were the most common readmission indications. Statistically significant risk factors reported included younger age, specific cancer types (e.g., acute lymphoblastic leukemia), and socioeconomic factors. Prevention strategies proposed included early follow-up, tailored anticipatory guidance, discharge education, and specialized care at pediatric oncology centers.
Conclusions: This systematic review highlights the multifaceted nature of hospital readmissions in pediatric oncology patients and the need for standardized definitions, additional studies, and comprehensive interventions. Future research should focus on high-quality prospective studies, integration of predictive analytics, and addressing socioeconomic disparities to improve patient outcomes.
期刊介绍:
Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.